Q - BridgeBio Pharma,
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
BBIO$77.93+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| License and services revenue | $37,440 | $2,168 | $117,130 | $213,288 |
| Net product revenue | 71,501 | — | 108,240 | — |
| Royalty revenue | 1,624 | — | 1,828 | — |
| Total revenues, net | 110,565 | 2,168 | 227,198 | 213,288 |
| Operating costs and expenses: | ||||
| Cost of revenues: | ||||
| Cost of license, services and royalty revenue | 805 | 598 | 1,410 | 1,196 |
| Cost of goods sold | 2,848 | — | 4,882 | — |
| Total cost of revenues | 3,653 | 598 | 6,292 | 1,196 |
| Research and development | 111,231 | 114,695 | 222,662 | 255,667 |
| Selling, general and administrative | 129,154 | 59,523 | 235,519 | 125,330 |
| Restructuring, impairment and related charges | 805 | 2,891 | 1,375 | 6,291 |
| Total operating costs and expenses | 244,843 | 177,707 | 465,848 | 388,484 |
| Loss from operations | (134,278) | (175,539) | (238,650) | (175,196) |
| Other income (expense), net: | ||||
| Interest income | 3,898 | 5,195 | 9,283 | 9,270 |
| Interest expense | (37,637) | (22,937) | (79,778) | (46,408) |
| Gain on deconsolidation of a subsidiary | — | 126,294 | — | 126,294 |
| Losses on extinguishments of debt | — | — | (21,155) | (26,590) |
| Net loss from equity method investments | (20,189) | (7,925) | (35,745) | (7,925) |
| Other income (expense), net | 6,548 | (632) | 14,779 | 8,851 |
| Total other income (expense), net | (47,380) | 99,995 | (112,616) | 63,492 |
| Loss before income taxes | (181,658) | (75,544) | (351,266) | (111,704) |
| Income tax expense | 2,100 | — | 2,100 | — |
| Net loss | (183,758) | (75,544) | (353,366) | (111,704) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 1,855 | 2,088 | 4,041 | 3,032 |
| Net loss attributable to common stockholders of BridgeBio | $(181,903) | $(73,456) | $(349,325) | $(108,672) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.95) | $(0.39) | $(1.84) | $(0.59) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 190,517,215 | 187,586,680 | 190,332,261 | 183,145,995 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.